Cord Blood Cells Showed Modest Benefits in Autism Trial
A small trial tested whether repeated donor cord blood cell infusions could safely influence social symptoms in children with autism and blood signs of immune dysregulation.
Category: News
Capricor Therapeutics to Present Cardiosphere-Derived Cell Therapy Trial and Open-Label Extension Data at World Muscle Society Congress
The analyses track skeletal muscle and heart outcomes through 24 months in 82 of 106 randomized participants, including delayed-start and natural-history comparisons submitted with a regulatory amendment.
Kincell Bio and Cellipont Bioservices Merge to Form Kincellis Advanced Therapies
The combined company operates 16 qualified manufacturing suites across three U.S. sites, supporting cell therapy programs from early development through commercial supply.
Ernexa Therapeutics Reports Positive Preclinical iPSC-Derived Mesenchymal Stem Cell Study, Advances Oncology Strategy
In mice with collagen-induced arthritis, several ERNA-201 candidates lowered disease severity versus untreated controls, while the company shifts near-term spending to ERNA-101’s planned ovarian cancer trial filing.
Cellares and GenomeFrontier Therapeutics Partnering on Automated Virus-Free CAR-T Program for Phase 1
The project will test whether GenomeFrontier’s virus-free process, including electroporation-based transfection, can be adapted to Cellares’ automated system to support U.S. clinical manufacturing.
Ultragenyx Announces Approval of Fayuvi Gene Therapy for Sanfilippo Syndrome Type A
The approval was based on a trial comparing 17 treated children with 27 untreated peers, with follow-up extending to nearly eight years and shipments expected within 30 to 60 days.
ZEO ScientifiX to Expand Umbilical-Cord Stem Cell Offerings to Georgia and Tennessee as New Regenerative Medicine Laws Take Effect
The move is aimed at helping providers meet the new states’ rules on sourcing, consent, documentation and safety reporting, which do not replace federal requirements or FDA approval.
Longeveron Stem Cell Phase 2b for Hypoplastic Left Heart Syndrome Misses Primary Endpoint
In the 40-infant randomized, double-blind trial, patients received a single intramyocardial dose. It did not improve right ventricular ejection fraction at 12 months.
JAX-NYSCF Stem Cell Toolkit for Parkinson’s Disease
Backed by $6.4M in grants, the team will create and validate more than 20 patient-derived stem cell lines, then share the cells, protocols and data publicly.
Cyllene Therapeutics’ Gene Therapy Receives FDA RMAT Designation for Neurogenic Detrusor Overactivity
The designation was based on early U.S. trial data in spinal cord injury patients, where this non-replicating HSV-1 gene therapy is being tested as a single-course treatment aimed at reducing bladder overactivity...